EGFR and lung carcinoma: The EGFR-AS1 lncRNA is a predictor of the therapeutic response to erlotinib, an anticancer drug that targets epidermal growth factor receptor (EGFR), in that erlotinib-resistant lung cancer cell lines expressed very low levels of EGFR-AS1 [131].